Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings reported Q2 2021 revenue of $2.2 million, slightly down from $2.3 million in Q2 2020. The gross margin improved to approximately 58% from 56% year-over-year, driven by better margins on EksoWorks products. Notably, the company successfully booked 20 EksoNR units, including 11 subscriptions. Despite an increased net loss of $1.3 million compared to $11.8 million in Q2 2020, the company holds a strong cash position of $45.9 million as of June 30, 2021, indicating stable financial health.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its Q2 2021 financial results on July 29, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results and recent business developments. Investors can access a live webcast on the company's website. A replay will be available for two weeks post-call. Ekso Bionics specializes in exoskeleton technology for medical and industrial applications, aiming to enhance human capabilities. The company is headquartered in the San Francisco Bay Area.

Ekso Bionics (Nasdaq: EKSO) has expanded its partnership with Kindred Healthcare by introducing the EksoNR robotic exoskeleton in four Long-Term Acute Care hospitals in Florida. Following a successful pilot program, this expansion aims to improve patient recovery from serious injuries and illnesses, including strokes and spinal cord injuries. The EksoNR has been recognized for its effectiveness in rehabilitation, and its deployment in these hospitals reflects a commitment to enhancing patient care. This strategic move is expected to bolster Ekso's presence in the healthcare market.

Ekso Bionics reported a 30% revenue increase for Q1 2021, totaling $1.9 million, compared to $1.5 million in Q1 2020. The company achieved a record gross margin of 65%, up from 43% year-over-year. Cash reserves surged to $49.5 million from $12.9 million at the end of 2020, bolstered by a $40 million public offering. The subscription model has facilitated sales to key rehabilitation operators, indicating strong market traction. However, a net loss of $3.7 million was recorded, compared to $2.5 million in the previous year.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q1 2021 after market close on April 29, 2021. A conference call will follow at 1:30 p.m. PT to discuss these results and recent developments. Investors can access the call via phone or through a live webcast on the company’s website. A replay will be available for two weeks post-call. Founded in 2005, Ekso Bionics specializes in exoskeleton solutions that enhance strength and mobility for medical and industrial applications.

Ekso Bionics Holdings (Nasdaq: EKSO) has announced a partnership with U.S. Physiatry (USP) to educate healthcare professionals on the clinical benefits of the EksoNR exoskeleton. USP, the largest physician practice focused on physical medicine in the U.S., will conduct a four-part lecture series aimed at enhancing the integration of Ekso's technology into rehabilitation programs. The initiative seeks to raise awareness and promote the economic value of the EksoNR, which is noted as the most studied exoskeleton available, potentially benefiting thousands of patients.

Ekso Bionics Holdings (Nasdaq: EKSO) has partnered with Performance Contracting, Inc. (PCI) to test its EVO™ exoskeleton vests in the construction sector. Over a year, PCI employees across six Bay Area counties will evaluate the technology to enhance product development. The EVO vest aims to reduce worker fatigue and injuries, boosting productivity. Michael Pratt of Ekso highlighted the importance of supporting their user base through flexible subscription offerings. PCI, emphasizing its commitment to employee well-being, plans to invest in innovative solutions to uphold its safety standards.

Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology, announced that CFO Jack Glenn will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. An on-demand presentation will be available starting at 4:00 AM PT / 7:00 AM ET on March 9 and accessible throughout the conference via the company's website. Ekso Bionics specializes in innovative solutions that enhance strength, endurance, and mobility in both medical and industrial sectors, highlighting their commitment to advancing wearable robotics since 2005.

Ekso Bionics Holdings reported a Q4 2020 revenue of $2.3 million, down from $3.7 million in Q4 2019, with gross margins improving to approximately 60%. The company saw a net loss of $4 million ($0.48 per share) for the quarter, compared to $2.7 million in 2019. Full-year revenue was $8.9 million, a decrease from $13.9 million in 2019, largely attributed to COVID-19 impacts. Despite a 45% reduction in cash used for operations, the company raised $40 million from a public offering in February 2021 to bolster its growth strategy.